tradmap

ASTC ASTROTECH Corp

$4.87 -0.31%

Data as of close

Healthcare · Laboratory Analytical Instruments

ASTROTECH Corp (ASTC) is a healthcare company in the Laboratory Analytical Instruments industry, with a market capitalization of $10 million. Shares last traded at $4.87, 92.9% below their 52-week high. Over the past year the stock is down 2.6%. Net profit margin is -848.1%, below the peer median of 1.9%. Revenue declined 13.0% year over year.

Market Cap
$10M
Shares Out
2.0M
EPS (TTM)
-$8.49
P/E (TTM)*
—
P/S Ratio
5.75
P/B Ratio
0.61
Dividend / Share
—
Dividend Yield
—
52-Week High
$68.63
52-Week Low
$2.20
Volume (venue)
113
Avg Vol (3m, venue)
1,839.825

* P/E (TTM) = market cap ÷ net income over the trailing twelve months where four consecutive quarters are reported, otherwise the latest fiscal year — the same basis as the peer table and the screener, so it can differ from price ÷ EPS.

Performance

1W
-4.13%
1M
-33.15%
3M
-33.01%
6M
+50.77%
YTD
+40.96%
1Y
-2.60%

Daily candles · volume · SMA(20)/SMA(50) · Databento EQUS.MINI.

Technicals

RSI (14)
32.57
SMA (50)
$6.49
SMA (200)
$7.33
Price vs SMA50
-24.95%
Price vs SMA200
-33.58%
ATR (14)
$0.31

Full technical analysis (26 indicators, D/W/M) →

Financials

Revenue
$2M
Net Income
-$14M
Gross Margin
12.8%
Operating Margin
-831.2%
Net Margin
-848.1%
Return on Equity
-89.2%
Return on Assets
-70.3%
Current Ratio
7.06
Debt / Equity
0.00
Revenue Growth (YoY)
-13.0%

Trailing twelve months where four consecutive quarters are reported, otherwise the latest fiscal year; revenue is the fiscal-year figure where quarterly revenue covers under half of it (typical for banks, insurers and REITs), and margins are taken on it; latest reported period ends 2026-06-30. Source: SEC EDGAR/XBRL.

Full financials — revenue, cash flow & debt over time →

Recent earnings

PeriodEPS (diluted)Reported
Q4 2026 (derived) -$1.83 2026-09-25
FY 2026 -$8.49 2026-09-25
Q3 2026 -$2.25 2026-05-13
Q2 2025 -$2.34 2026-02-13
Q1 2025 -$2.07 2025-11-13
Q4 2025 (derived) -$1.68 2025-09-26

Q4 marked "derived" = fiscal-year EPS minus Q1–Q3 (10-Ks report only the annual figure); EPS is not strictly additive, so it can differ by a cent or two from the issuer's own Q4.

Full earnings history →

Laboratory Analytical Instruments peers

ASTC vs 14 industry peers (Laboratory Analytical Instruments), by market cap. Data as of close

P/S vs peers
5.75 / 4.80 med
+20% premium
Net margin vs peers
-848.1% / 1.9% med
below median
1–14 of 14
AAgilent Technologies$48.5B33.686.5819.5%-1.62%
WATWaters Corporation$44.2B68.719.5113.8%-2.86%
ILMNIllumina, Inc.$34.2B38.267.5519.7%-4.10%
MTDMettler Toledo$33.6B37.148.1421.9%+0.17%
RVTYRevvity$16.9B71.265.818.2%-3.38%
AVTRAvantor, Inc.$10.6B31.351.595.1%-2.86%
BIOBio-Rad Laboratories, Inc.$9.8B44.033.788.6%-1.57%
BRKRBruker Corp$8.5B—2.42-2.0%-2.48%
TXG10x Genomics, Inc.$8.0B—13.01-12.2%-12.14%
ALMRAlamar Biosciences, Inc.$2.0B———-5.48%
CTKBCytek Biosciences, Inc.$751M—3.63-32.2%-5.56%
PACBPacific Biosciences Of California, Inc.$727M———-10.34%
MASS908 Devices Inc.$421M—6.92-57.0%-9.26%
NAUTNautilus Biotechnology, Inc.$302M———-13.50%

Source: SEC EDGAR (fundamentals/EPS/dividends) · Databento EQUS.MINI (prices) · market cap & yield computed by tradmap. Informational only — not financial advice.